Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from MIRA Pharmaceuticals, Inc. ( (MIRA) ) is now available.
MIRA Pharmaceuticals announced the FDA clearance of its IND application for Ketamir-2, allowing the initiation of U.S.-based clinical trials for this non-opioid drug candidate aimed at treating neuropathic pain. The company is advancing through Phase 1 trials and plans to start Phase 2a trials by the end of 2025. Additionally, MIRA is progressing with the acquisition of SKNY Pharmaceuticals and the development of MIRA-55, which has shown promising results in preclinical studies.
The most recent analyst rating on (MIRA) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on MIRA Pharmaceuticals, Inc. stock, see the MIRA Stock Forecast page.
More about MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing novel oral drug candidates. The company targets neuropathic pain and other conditions with products like Ketamir-2, an NMDA receptor antagonist, and has ongoing programs in obesity, nicotine craving, and inflammatory pain.
Average Trading Volume: 1,478,912
Technical Sentiment Signal: Strong Buy
For an in-depth examination of MIRA stock, go to TipRanks’ Overview page.